General Information
Manufacturer: Amgen/AstraZeneca
Medical Name: Tezepelumab-ekko
Purpose: Tezspire is a prescription medicine used with other asthma medicines for the maintenance treatment of severe asthma and used with other medicines for the maintenance treatment of chronic rhinosinusitis
Possible Side Effects
| Adverse Reaction | Likelihood with Tezspire | Likelihood with Placebo Reference |
|---|---|---|
| Pharyngitis (sore throat) | 4% | 3% |
| Arthralgia (joint pain) | 4% | 3% |
| Back pain | 4% | 3% |
Other Adverse Effects
| Adverse Reaction | Likelihood with Tezspire | Likelihood with Placebo Reference |
|---|---|---|
| Nasopharyngitis (common cold symptoms) | 21.4% | 21.5% |
| Upper respiratory tract infection | 11.2% | 16.4% |
| Headache) | 8.1% | 8.5% |
Serious Side Effects
- Hives, rash, or itching
- Swelling of the face, mouth, or tongue
- Trouble breathing
- Lightheadedness or fainting
Serious Precautions
| Precaution | Description |
|---|---|
| Allergies | Do not use Tezspire if you are allergic to tezepelumab-ekko or any of its ingredients. |
| Corticosteroids | Do not abruptly stop taking oral or inhaled corticosteroids without a doctor's supervision, as the dosage should be reduced gradually. |
| Infections | Patients with a pre-existing parasitic (helminth) infection should be treated before starting Tezspire. |
| Vaccines | The use of live attenuated vaccines should be avoided while on Tezspire therapy. |
Preconditions
| Precondition | Description |
|---|---|
| Hypersensitivity | Tezspire is contraindicated in patients with a known hypersensitivity to tezepelumab or any of its ingredients. Hypersensitivity reactions, including rash, allergic conjunctivitis, and anaphylaxis, have been reported and can be immediate or delayed. |
| Acute Asthma Symptoms | Tezspire should not be used to treat acute asthma symptoms, acute bronchospasm, or status asthmaticus. It is an add-on maintenance treatment for severe asthma, not a rescue medication. |
| Pre-existing Helminth (Parasitic) Infections | Patients with pre-existing helminth infections should be treated for the infection before starting Tezspire. There are limited data on the effect of Tezspire on the immune response to these infections. |
| Live Attenuated Vaccinations | Patients receiving Tezspire should not receive live attenuated vaccines. |
| Age Limitations | The safety and efficacy of Tezspire have only been established for patients 12 years of age and older. |